Navigation Links
Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018

DUBLIN, Dec. 16, 2013 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018" report to their offering.

Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules since chemotherapy, which is the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly. In addition, it affects the normal cells in the body.

Likewise, peptide application in various other treatments has opened a promising avenue for future growth of this market. New routes of peptide administration are being investigated; however the parenteral route continues to dominate this market and accounted for a share of almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (long phase peptide syntheses) and is anticipated to decline owing to huge demand for solid phase peptide syntheses and hybrid syntheses.

This report analyzes the peptide therapeutics market by types of applications (cancer, metabolic, neurological diseases and others), route of administration, by types (innovative and generic), by API therapeutics market (in-house vs. CMO), by peptide therapeutics, and technology. Each of these markets is analyzed by studying the current and future market scenario, with estimation for the period 2010 - 2018 in terms of value in USD million.

Key Topics Covered:

1 Introduction
1.1 Report description
1.2 Market segmentation
1.3 Scope of the report
1.4 Research methodology
1.5 Assumptions

2 Executive Summary

3 Global Peptide Therapeutics Market Dynamics
3.1 Overview
3.2 Drivers
3.3 Restraints & challenges
3.4 Opportunities
3.5 Porters five forces analysis
3.6 Market attractiveness analysis
3.7 Peptide therapeutics - emerging technologies & trends
3.8 Regulatory policies

4 Global Peptide Therapeutics Market Analysis, By Applications

5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.2 Parenteral Route
5.3 Oral Route
5.4 Pulmonary Route
5.5 Mucosal Route
5.6 Others (Intradermal & Nasal)

6 Peptide Therapeutics Market - Generic & Innovative Segments
6.1 Introduction
6.2 Peptide Therapeutics - Innovative market
6.3 Peptide Therapeutics - Generic market

7 API Peptide Therapeutics Market, In-house Vs CMO
7.1 Introduction
7.2 API peptide therapeutics - In-house market
7.3 Contract Manufacturing Organizations (CMO)

8 Peptide Therapeutics Market, By Technology
8.1 Introduction
8.2 Solid Phase Peptide Synthesis (SPPS)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.4 Hybrid Technology

9 Peptide Therapeutics Market, By Geography
9.1 Introduction
9.2 North America
9.3 Europe
9.4 Asia
9.5 Rest of World

10 Market Share Analysis
10.1 Market share by key players
10.2 Market share by key players in peptide drugs market
10.3 Market share by key players in CMO segment

11 Recommendations
11.1 Success strategies
11.2 Barriers to be considered

12 Company Profiles

Companies Mentioned:

  • Amgen, Inc.
  • Amylin Pharmaceuticals LLC Bristol-Myers Squibb (BMS)
  • AstraZeneca PLC
  • Bachem Holding AG
  • Eli Lilly and Company
  • GlaxoSmithKline (GSK)
  • Ipsen
  • Lonza Inc.
  • Merck & Co.
  • Novartis AG
  • Novo-Nordisk A/S
  • Peptisyntha
  • Pfizer, Inc.
  • PolyPeptide Group.
  • Roche
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals

For more information visit

Media Contact:

Laura Wood , +353-1-481-1716,

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
2. Poster & Abstract Entitled 1H-MRS & FDG-PET Studies in the SOD1 G93A - the Use of Stabilized Peptides as a Rationale for Future Treatment in ALS Presented During Annual Northeast ALS Consortium Meeting
3. US Peptides Discusses the Benefit of Human Growth Hormone
4. CEM Wins Peptide Patent Dispute with Biotage
5. Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
6. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
7. US Peptides Discusses the Benefit of Human Growth Hormone and IGF-1
8. Innovative Research Collaboration to Advance Next-Generation Methods in Peptide Discovery for Cosmeceuticals
9. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
10. Tarix Pharmaceuticals Peptide Technology Stimulates Revascularization Following Ischemia
11. US Peptides Discusses IGF 1 in new article series
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... --> --> Opportunities ... and PPAR Agonists cholesterol-lowering drugs market ? ... rates? This visiongain report shows you potential ... there. ,  ,Our 199-page report provides 153 tables, charts, ... industry and the future market prospects. Our new study ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... it comes to several aspects of orthopedic care. They have received recognition for ... and general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to ... it is critical that the first impression be positive and reflects business values. If ... to buy anything or want to return. They will also share their thoughts about ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... advisory organization, is pleased to welcome Winter-Dent & Company as its newest Partner ... day one to become a client's most trusted advisor regardless of whether that ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... States to support their local poison centers through donations on Tuesday, Dec. 1, ... calls it “a day that inspires people to collaborate in improving their local ...
Breaking Medicine News(10 mins):